Motilal Oswal Group entities—India Business Excellence Fund IV (via MO Alternate Investment Advisors) and Motilal Oswal Finvest—have acquired over 60% of Megafine Pharma for approximately ₹460 crore.

Pioneer Legal advised and assisted Megafine Pharma and its promoters on this transaction.

The transaction team consisted of Satish Kishanchandani (Managing Partner), Anupam Shukla (Partner), Vedika Shah (Senior Associate), Shreya Masalia and Shivaansh Gulati (Associates).

JSA represented a continuing promoter group on this transaction.

Quillon Partners acted for Motilal Oswal on this transaction.

This strategic investment aims to bolster Megafine's research and development capabilities, expand its manufacturing operations, and pursue inorganic growth opportunities. According to Business Standard, the transaction involved the Sanghvi family, a founding promoter group, increasing their stake, while the Jhaveri and Gandhi families exited the company. This deal signifies MO Alts' confidence in the growing Indian Active Pharmaceutical Ingredient (API) industry and its intent to create a robust pharmaceutical platform

Megafine Pharma is a Mumbai-based, export-focused company specialising in the production of Active Pharmaceutical Ingredients (APIs). Established in 1995, the company operates two USFDA-approved manufacturing facilities located in Nashik and Vapi. Megafine focuses on manufacturing high-value, low-volume niche APIs, primarily for chronic therapies.

Motilal Oswal Alternates is the alternative investment platform of Motilal Oswal Financial Services Ltd. It manages various alternative investment funds, including private equity, real estate, and venture capital funds. MO Alts focuses on identifying and investing in high-growth potential companies across diverse sectors.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.